- Home
- DAWN vs TRNR Comparison
DAWN vs TRNR Comparison
Compare DAWN & TRNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- TRNR
- Stock Information
- Founded
- DAWN 2018
- TRNR 2017
- Country
- DAWN United States
- TRNR United States
- Employees
- DAWN N/A
- TRNR N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- TRNR Consumer Electronics/Appliances
- Sector
- DAWN Health Care
- TRNR Technology
- Exchange
- DAWN Nasdaq
- TRNR Nasdaq
- Market Cap
- DAWN 1.3B
- TRNR 836.6K
- IPO Year
- DAWN 2021
- TRNR 2023
- Fundamental
- Price
- DAWN $12.79
- TRNR $2.92
- Analyst Decision
- DAWN Strong Buy
- TRNR
- Analyst Count
- DAWN 7
- TRNR 0
- Target Price
- DAWN $36.17
- TRNR N/A
- AVG Volume (30 Days)
- DAWN 1.0M
- TRNR 1.9M
- Earning Date
- DAWN 10-30-2024
- TRNR 11-14-2024
- Dividend Yield
- DAWN N/A
- TRNR N/A
- EPS Growth
- DAWN N/A
- TRNR N/A
- EPS
- DAWN N/A
- TRNR N/A
- Revenue
- DAWN $101,953,000.00
- TRNR $3,180,000.00
- Revenue This Year
- DAWN N/A
- TRNR $1,543.45
- Revenue Next Year
- DAWN $36.10
- TRNR $54.84
- P/E Ratio
- DAWN N/A
- TRNR N/A
- Revenue Growth
- DAWN N/A
- TRNR 226.82
- 52 Week Low
- DAWN $11.94
- TRNR $2.50
- 52 Week High
- DAWN $18.07
- TRNR $4,760.00
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- TRNR 35.17
- Support Level
- DAWN $12.26
- TRNR $2.85
- Resistance Level
- DAWN $12.81
- TRNR $3.40
- Average True Range (ATR)
- DAWN 0.52
- TRNR 0.33
- MACD
- DAWN -0.05
- TRNR 0.41
- Stochastic Oscillator
- DAWN 28.94
- TRNR 30.69
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.